April 11, 2017
Sponsored by
Personal Genome Diagnostics

Genomic Predictors of Immunotherapy Response

GenomeWebinar

Director of Ambulatory Treatment Center and Emergency Care, Director of Hematology/Oncology for The University of Texas, Houston Internal Medicine Residency Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Oncology Science Liaison, PGDx

This webinar provides an overview of genomic alterations that play a role in immunotherapy response.

Impressive response rates to checkpoint inhibitors have been observed in subsets of tumors with high tumor mutational burden due to mutations in DNA polymerase epsilon (POLE) and mismatch repair genes (MMR) across histologies. Mutations in the MMR pathway lead to microsatellite instability (MSI), which is characterized by alterations in the length of repeated DNA microsatellite sequences. The MSI phenotype was originally described for inherited tumors associated with Lynch syndrome and was later identified in sporadic tumors. The prevalence of MSI is higher in colorectal, endometrial, and gastric cancers, but MSI has been observed in many tumor types at varying frequencies.

In this webinar, Dr. Michael Overman of the University of Texas MD Anderson Cancer Center discusses the molecular mechanisms of immunotherapy response. In particular, he provides evidence that MSI-high and other hyper-mutated tumors have large numbers of neoantigens to which the immune system can respond when primed by checkpoint blockade. 

Sponsored by

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Sep
21
Sponsored by
Roche

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
27
Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Oct
12
Sponsored by
PierianDx

This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers. 

Oct
17
Sponsored by
Cofactor Genomics

This webinar will discuss the benefits of genomically profiling the immune microenvironment of soft tissue sarcomas during neoadjuvant therapy.